US equities
|
MU
$907.04
▼-0.78%
NVDA
$217.10
▼-1.90%
SNDK
$1,348.11
▼-3.94%
SPCX
$147.45
▼-3.09%
AMD
$551.80
▼-3.33%
INTC
$93.96
▼-4.24%
AAPL
$342.44
▼-0.15%
CRWV
$68.14
▲+3.58%
MU
$907.04
▼-0.78%
NVDA
$217.10
▼-1.90%
SNDK
$1,348.11
▼-3.94%
SPCX
$147.45
▼-3.09%
AMD
$551.80
▼-3.33%
INTC
$93.96
▼-4.24%
AAPL
$342.44
▼-0.15%
CRWV
$68.14
▲+3.58%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Vanda Pharmaceuticals Inc. - Common Stock
(NQ:
VNDA
)
4.245
+0.025 (+0.59%)
Delayed Quote
Updated: 2:46 PM EDT, Oct 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vanda Pharmaceuticals Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Cel-Sci Stock Shows Market Leadership With Jump To 81 RS Rating
↗
June 17, 2021
Cel-Sci sees its Relative Strength Rating hit the 80-plus level.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2021
↗
May 12, 2021
Upgrades Craig-Hallum upgraded the previous rating for ShotSpotter Inc (NASDAQ:SSTI) from Hold to Buy. For the first quarter, ShotSpotter had an EPS of $0.02, compared to...
Via
Benzinga
Altimmune Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
↗
May 11, 2021
On Tuesday, Altimmune stock received a positive adjustment to its Relative Strength Rating, from 78 to 86. The biopharma stock is worth watching.
Via
Investor's Business Daily
Vanda Pharmaceuticals Inc (VNDA) Q1 2021 Earnings Call Transcript
↗
May 05, 2021
VNDA earnings call for the period ending December 31, 2020.
Via
The Motley Fool
Topics
Earnings
Earnings Scheduled For May 5, 2021
↗
May 05, 2021
Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter. • EyePoint Pharmaceuticals (NASDAQ:EYPT...
Via
Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
↗
May 01, 2021
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...
Via
Benzinga
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
↗
May 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
